Heart Plaque Camera Sees Risk Before Arteries Narrow

The Heart Plaque Camera trial has reached a milestone that cardiologists have wanted for years: a tiny catheter that can look inside a beating heart's arteries and read both the structure of plaque and the chemistry that makes it dangerous. Researchers have just finished testing the device in people for the first time, and the early results suggest doctors may soon be able to spot risky buildup before it narrows a vessel enough to cause trouble.

According to the university team behind the work, the flexible catheter slides through coronary vessels while the heart is beating, gathering colour images of the artery wall as it is pulled back. In a single pass it pairs two kinds of light measurement: one that reads the faint natural glow of tissue to reveal its biochemical makeup, and another that maps the fine structure of the wall from scattered light. Until now, standard heart catheter exams could show structure but not chemistry, leaving doctors to guess which plaques were most likely to rupture.

That gap matters because not all plaque behaves the same way. Some deposits sit quietly for years, while others become inflamed, weaken and tear open, triggering a clot that can block blood flow and cause a heart attack. A tool that flags inflamed or unstable plaque early could change how doctors choose between watchful monitoring, medication and a stent, and it could help them place a stent exactly where it will do the most good. The new device was designed for that decision point, inside the artery itself rather than from an outside scan.

How the Dual-Imaging Catheter Works

The catheter carries two imaging methods in one slim body. The first method, fluorescence lifetime imaging, measures the faint natural fluorescence of the artery wall, which reflects its biochemical composition. The second, a polarisation-sensitive form of optical coherence tomography, measures light scattered back from the same tissue to map its microstructure. Together they produce a combined picture during one pullback, the slow withdrawal of the catheter while it records.

Speed is part of the appeal. In the human tests, the device imaged a stretch of coronary artery measuring 80 millimetres in about two seconds as it was drawn back, fast enough to keep pace with a beating heart. That pace matters in a real catheter lab, where doctors work inside living, moving vessels and cannot pause the heart to take a leisurely picture. The catheter was previously tested in animal models and in samples of human coronary arteries before the team received approval to try it in patients.

The human study itself was deliberately small, as first-in-human trials usually are. The team received approval this year to evaluate the technology in ten patients, and in August it completed imaging for the final participant. The point of such an early trial is not to prove that the device prevents heart attacks, which would take a far larger study, but to show that it can be used safely in people and that the images it returns are clear, consistent and clinically meaningful.

Why Earlier Warning Could Change Treatment

Heart disease remains the leading cause of death in the United States, and plaque buildup in the arteries can lead to heart attack, stroke and other serious conditions. Today, when a vessel narrows enough to restrict flow, treatment often involves placing a stent, a small mesh tube that props the artery open. How and where that stent is placed, and which drugs accompany it, affect how well it holds up over time. A clearer picture of plaque composition before the narrowing becomes severe could let doctors intervene sooner, or in some cases hold off on a stent that is not yet needed.

The Heart Plaque Camera approach also highlights a broader shift in cardiology: from treating blockages after they appear toward reading the biology of the vessel wall itself. A plaque that looks modest on a structural scan may be chemically unstable, while a larger plaque may be stable and calcified. Telling those apart in the catheter lab, in real time, could spare some patients unnecessary procedures and steer others toward closer monitoring or stronger preventive therapy. That distinction is the heart of personalised heart care, and it is why the team calls this step a major advance for the field.

There are limits to keep in view. A first-in-human study with a small group cannot settle questions about long-term outcomes, and the device will need larger trials, regulatory review and head-to-head comparisons with existing imaging before it reaches routine use. Some clinicians may also ask whether the extra information changes decisions enough to justify the added complexity in a busy lab. Those are fair questions, and the researchers say the next step is to scale up the study to include more patients so the answers rest on stronger evidence rather than early promise.

What happens next will be watched well beyond one hospital. If larger trials confirm that combined chemistry and structure readings predict which plaques rupture, catheter labs could adopt the approach for assessing plaque composition and guiding stent placement, and the same dual-imaging idea could be adapted for other vessels where unstable deposits cause strokes. For now, the milestone is modest but real: a laboratory-built catheter has survived its first test in human hearts and returned images that doctors can actually use. For related health reporting, see a hidden reservoir clue in cure research and a long-term study of radon and brain cancer risk. The team also notes that late-night phone use is pushing teen bedtimes later, a reminder that everyday habits shape heart health too.